Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134) Meeting Abstract
| Authors: | Jensen, R. E.; Zheng, Y.; Atkins, M. B.; Chmielowski, B.; Tarhini, A. A.; Truong, T. G.; Davar, D.; O'Rourke, M. A.; Curti, B. D.; Brell, J. M.; Kendra, K. L.; Ikeguchi, A.; Lee, S. J.; Potosky, A. L.; Wolchok, J. D.; Ribas, A.; Kirkwood, J. M.; Wagner, L. I.; Cella, D. |
| Abstract Title: | Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302378 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.9559 |
| Notes: | Meeting Abstract: 9559 -- Meeting also held virtually -- Source: Wos |
